ARCHIVES

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

This article is from The Cancer Letter archive.

Vol. 32 No. 8 | August 28, 2009

Download PDF Visit The Full Archive

Related Articles

Clinton Administration Issues Research Misconduct Policy.

December 8, 2000

60 Minutes Report “Deception at Duke” Wins Peabody Award

March 29, 2013

NCI Advisory Group, Other Cancer Meetings

January 2, 1981

NCAB Sets Bypass Budget Figures at $1.074 Billion

May 28, 1982

Cooperative Groups Pursue Contracts With Insurers, NCI Warns of Competition

June 14, 1996

Remarks on HPV Vaccines, SPORE Funds Create Controversy for NCI’s John Niederhuber.

April 14, 2006